Genprex Aktie [WKN DE: A2JHMQ / ISIN: US3724461047]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Genprex Inc Registered Shs

09.02.22		Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes (Businesswire)
27.01.22		Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer (Businesswire)
10.01.22		Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer (Businesswire)
05.01.22		Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes (Businesswire)
04.01.22		Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer (Businesswire)
03.01.22		Genprex Receives FDA Fast Track Designation For REQORSA - Keytruda For NSCLC Treatment (RTTNews)
03.01.22		Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
23.06.21		Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review (Businesswire)
19.05.21		Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series (Businesswire)
10.05.21		Genprex to Participate in Upcoming May Investor Conferences (Businesswire)
06.05.21		Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer (Businesswire)
05.05.21		Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer (Businesswire)
04.05.21		Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
21.04.21		Genprex to Participate in CEO Roadshow Webinar Series (Businesswire)
20.04.21		Genprex to Receive Inaugural "License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes (Businesswire)
12.04.21		Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting (Businesswire)
05.04.21		Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean (Businesswire)
30.03.21		Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting (Businesswire)
24.03.21		Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29 (Businesswire)
01.03.21		Genprex to Participate in Upcoming March Investor Conferences (Businesswire)
09.02.21		Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants (Businesswire)
08.02.21		Genprex Announces Formation of Clinical Advisory Board (Businesswire)
04.02.21		Genprex Recognizes World Cancer Day (Businesswire)
01.02.21		Genprex Issues Shareholder Letter and Provides Corporate Update (Businesswire)
27.01.21		Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 (Businesswire)
14.01.21		Genprex to Present at NobleCon17 on January 19 (Businesswire)
13.01.21		Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer (Businesswire)
24.12.20		Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants (Businesswire)
22.12.20		Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants (Businesswire)
22.12.20		Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer (Businesswire)
08.12.20		Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy (Businesswire)
03.12.20		Genprex to Present at the Benzinga Global Small Cap Conference on December 8 (Businesswire)
30.11.20		Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer (Businesswire)
24.11.20		Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 (Businesswire)
11.11.20		Genprex to Participate in Panel at Life Sciences Summit on November 17 (Businesswire)
10.11.20		Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD (Businesswire)
30.10.20		Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer (Businesswire)
29.10.20		Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer (Businesswire)
26.10.20		Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing (Businesswire)
07.10.20		Genprex to Present at Zooming with LD Micro on October 14, 2020 (Businesswire)
06.10.20		Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa (Businesswire)
21.09.20		Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing (Businesswire)
02.09.20		Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs (Businesswire)
31.07.20		Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020 (Businesswire)
30.07.20		Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show” (Businesswire)
23.07.20		Pre-market Movers In Healthcare Sector: ENTX, IMRN, CNTG, IMMP... (RTTNews)
21.07.20		National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex (Businesswire)
29.06.20		Genprex Added to Russell 3000® Index (Businesswire)
25.06.20		Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate (Businesswire)
24.06.20		Genprex CEO to Interview Live on "The Big Biz Show” (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Krypto-Influencer prognostiziert für 2025 gewaltige Rally beim Dogecoin

Solana Kurs-Prognose: 300 US-Dollar noch im Januar?

Pierer Mobility-Aktie knickt ein: KTM wird Produktionsstopp womöglich verlängern

Zinspolitik 2025: EZB plant Senkungen - wie schnell kommen sie?

Tesla-Aktie sackt ab: Absatzzahlen bleiben hinter Erwartungen

Apple-Aktie unter Druck: Apple kämpf offenbar mit China-Konkurrenz

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.01.2025 09:42
Kaufwert:	EUR
	Hinzufügen Speichern